New Prostate Cancer Screening Guidelines: What Men Should Know

In November 2026, the American Cancer Society (ACS) updated its prostate cancer screening guidelines for the first time since 2010, shifting from a neutral “discuss with your doctor” stance to a direct recommendation for regular prostate-specific antigen (PSA) blood testing. Under the revised guidance, men at average risk are advised to get a PSA test every two years from ages 50 through 69, while Black men and men with a strong family history should begin annual screening at age 45. What many men misunderstand about PSA screening is that a high test result no longer triggers an automatic biopsy or aggressive surgery; modern clinical protocols use repeat blood tests, prostate MRIs, and active surveillance to catch dangerous tumors while leaving slow-growing ones alone.

The 2026 American Cancer Society prostate cancer screening recommendations advise regular PSA blood tests starting at age 50 for average-risk men (every two years) and age 45 for Black men and those with a close family history (every year or every two years, depending on when relatives were diagnosed). Men ages 70 to 74 should make an individualized decision with their doctor, and routine screening is discouraged at age 75 and older. The routine digital rectal exam is no longer recommended as a primary screening test.

What Changed in the 2026 ACS Guidelines (and Why)

Published in November 2026 in CA: A Cancer Journal for Clinicians (Hoffman et al.), the ACS prostate cancer screening guideline update was developed by an interdisciplinary panel of clinicians, epidemiologists, biostatisticians, and patient representatives. The group conducted a systematic evidence review and commissioned a modeling study comparing the long-term benefits and harms of various PSA screening schedules in asymptomatic men.

A central piece of human clinical evidence in the review was the 16-year follow-up of the European Randomized Study of Screening for Prostate Cancer (ERSPC), which found that invitations to PSA-based screening were associated with roughly a 20% relative reduction in prostate cancer mortality (relative risk 0.80; 95% confidence interval, 0.72 to 0.89).

In 2010, the ACS had stopped short of recommending routine testing because PSA screening often found slow-growing cancers that would not have threatened a man’s life, leading to unnecessary biopsies, surgeries, and radiation side effects. Two major clinical developments prompted the 2026 reversal:

• Smarter triage before biopsy: Clinicians now verify an elevated PSA with a repeat blood draw weeks later and use magnetic resonance imaging (MRI) or specialized blood and urine biomarkers before deciding whether a needle biopsy is needed.
• Widespread adoption of active surveillance: Men found to have low-risk prostate cancer are now routinely monitored with periodic tests rather than sent straight to surgery or radiation.

Who these guidelines do not apply to: Screening recommendations apply only to men without symptoms who have no personal history of prostate cancer. They do not apply to men already diagnosed with or treated for prostate cancer, or to men experiencing urinary or pelvic symptoms, who require diagnostic evaluation rather than routine screening. Furthermore, the ACS advises against screening men of any age whose other health conditions limit their life expectancy to less than 10 years, because prostate cancer typically develops slowly enough that early detection offers little survival benefit in that timeframe.

Who Should Be Screened, Starting When, and How Often

Even with a direct recommendation for regular testing, the ACS notes that clinicians should first make sure patients understand the benefits, limitations, and potential harms of PSA testing before drawing blood. Once a man decides to proceed, his starting age and testing interval depend on his personal risk profile.

• Average-risk men (ages 50 to 69): Screen with a PSA blood test every two years.
• Black men (ages 45 to 69): Begin PSA screening at age 45 and test every year through age 69, reflecting the higher incidence and mortality rates of prostate cancer in Black men.
• Non-Black men with a higher-risk family history (ages 45 to 69): Begin PSA screening at age 45 and test every year if a first-degree relative (father, brother, or son) was diagnosed with prostate cancer before age 65, or if more than one close relative has had prostate cancer.
• Non-Black men with a single later-onset family history (ages 45 to 69): Begin PSA screening at age 45 and test every two years if a single first-degree relative was diagnosed at age 65 or older.
• Men with inherited genetic mutations: Men who carry known high-risk germline mutations (such as BRCA2) or have a close relative with a linked gene mutation should talk with their clinician about an individualized starting age and frequency, which the American Urological Association (AUA) early detection guideline places at ages 40 to 45.
• Men ages 70 to 74: Because the balance of benefits and harms becomes less certain in a man’s early 70s, continuing to screen is an individualized decision made with a doctor. Men who choose to continue should test every two years.
• Men ages 75 to 79: Routine screening is not recommended. Exceptionally healthy men in this age group may consider continuing only after discussing it with their clinician, particularly if prior PSA readings have been trending upward.
• Men age 80 and older: Screening is discouraged under all circumstances.

How Major US Screening Guidelines Compare

Because major medical organizations update their guidance on different schedules and weigh the trade-offs of overdiagnosis differently, a primary care physician and a urologist may give slightly different advice. The table below compares the current positions of the three main US bodies alongside federal public health guidance.

Organization	Average-Risk Starting Age & Interval	High-Risk Starting Age (Black Men, Family History, Genetic Risk)	Guidance for Men 70 and Older	Role of Digital Rectal Exam (DRE)
American Cancer Society (2026 Update)	Ages 50–69: Recommend PSA every 2 years (after informed discussion)	Age 45: Annual PSA for Black men and strong family history; every 2 years if one relative diagnosed at 65+	Ages 70–74: Individualized decision (every 2 years if chosen). Age 75+: Not recommended (discouraged at 80+)	Not recommended as a screening test
American Urological Association / SUO (Amended 2026)	Ages 45–50: Baseline PSA may be offered. Ages 50–69: Regular PSA every 2–4 years	Ages 40–45: Offer screening for Black men, strong family history, or germline mutations	Personalize or discontinue based on health, PSA level, and life expectancy	Clinicians may use alongside PSA, though PSA is the primary screening tool
U.S. Preventive Services Task Force (2018; update in progress)	Ages 55–69: Individual decision after shared decision-making (Grade C)	Acknowledges higher risk in Black men and those with family history; does not set a separate formal starting age	Age 70+: Recommends against PSA-based screening (Grade D)	Not recommended as a screening test
Centers for Disease Control and Prevention (CDC)	Follows USPSTF: Ages 55–69 shared decision-making	Advises discussing personal risk factors with a doctor	Age 70+: Do not screen routinely	Notes USPSTF does not recommend DRE due to lack of evidence on benefits

For more on how federal public health agencies summarize these options for patients, see the CDC guide to prostate cancer screening.

What Most Articles Leave Out: An Elevated PSA Does Not Mean Straight to Biopsy

One reason men avoid PSA screening is the belief that a slightly high blood test will immediately put them on a conveyor belt toward an invasive prostate biopsy and life-altering surgery. The 2026 ACS guidelines explicitly lay out a multi-step buffer designed to prevent unnecessary procedures.

1. Age-Specific Cutoffs Instead of a Single Number

For years, a PSA of 4.0 ng/mL was treated as the universal cutoff between normal and abnormal. In reality, benign prostate enlargement naturally raises PSA as men get older. The 2026 ACS guideline establishes two distinct thresholds for further evaluation:

• Ages 45 to 69: A PSA level of 3.0 ng/mL or higher is considered elevated.
• Ages 70 to 74: A PSA level of 6.5 ng/mL or higher is considered elevated.

2. Mandatory Repeat Testing Before Action

According to the National Cancer Institute (NCI) PSA test fact sheet, about 6% to 7% of men receive a false-positive PSA result on any given screening round, and only about 25% of men who undergo a biopsy for an elevated PSA actually have cancer. PSA levels fluctuate naturally and can spike temporarily from a mild prostate inflammation, a urinary tract infection, recent ejaculation, vigorous cycling, or certain medical procedures.

Unless a man’s initial PSA is extremely high or paired with other strong signs of malignancy, the ACS recommends repeating the PSA test between 2 weeks and 3 months later to confirm the elevation before ordering further workup. To avoid an artificial spike on either a first or repeat test, the NCI notes that men are generally advised to avoid ejaculation and vigorous exercise that puts pressure on the perineum (such as bike riding) for two days before the blood draw, and to wait until any urinary infection resolves.

3. MRI and Biomarker Triage

If the repeat PSA test remains above the age threshold (3.0 ng/mL for men under 70; 6.5 ng/mL for men 70 and older), the next step for most men is not an immediate biopsy. Instead, clinicians offer a multiparametric prostate MRI and/or a validated blood or urine biomarker test (such as the Prostate Health Index, 4Kscore, or IsoPSA). These tools estimate the likelihood of clinically significant (high-grade) cancer, allowing men with reassuring scans and biomarker scores to avoid a needle biopsy altogether.

4. Active Surveillance for Low-Risk Findings

When a biopsy is needed and detects prostate cancer that has a low risk of growing or spreading, both the ACS and the AUA state that active surveillance should be offered as the initial management option. Active surveillance means closely monitoring the tumor with scheduled PSA tests, periodic MRIs, and occasional repeat biopsies, initiating surgery or radiation only if the cancer shows signs of becoming more aggressive.

What the Evidence Shows About Benefits and Harms

The U.S. Preventive Services Task Force prostate cancer screening recommendation and the NCI highlight why informed decision-making remains essential before a blood draw. Screening carries real benefits, but it cannot eliminate every risk.

• What screening can do: Regular PSA testing reduces the risk of being diagnosed with advanced, metastatic prostate cancer and lowers the likelihood of dying from the disease.
• What screening cannot do: A normal PSA cannot guarantee the absence of cancer, and early detection does not result in a cure for every patient; some aggressive tumors spread beyond the prostate while still small.
• The risk of overdiagnosis and complications: Even with MRI triage and active surveillance, screening still identifies some slow-growing tumors that would never have caused symptoms during a man’s lifetime (overdiagnosis). Biopsies carry small but real risks of pain, bleeding, and serious infection. For men who ultimately undergo surgery or radiation, potential long-term complications include urinary incontinence, bowel urgency or rectal bleeding, and erectile dysfunction.

Screening vs. Symptom Evaluation: A Commonly Confused Distinction

A frequent mistake is waiting for urinary changes before asking for a PSA test—or, conversely, assuming that a slow urine stream means you have prostate cancer.

Early-stage prostate cancer rarely causes noticeable symptoms. When men in their 50s, 60s, and 70s develop a weak urinary stream, hesitancy, or frequent nighttime trips to the bathroom, the culprit is most often benign prostatic hyperplasia (BPH) or non-cancerous prostate inflammation, both of which are far more common than malignancy.

However, if you already have urinary or pelvic symptoms, you are no longer a candidate for routine “screening”—you need a diagnostic evaluation to find the cause and get symptom relief. Schedule a prompt medical evaluation if you experience:

• Difficulty starting urination, a weak or interrupted flow, or feeling unable to empty your bladder
• Painful or burning urination
• Blood in your urine or semen
• Persistent, unexplained pain in your lower back, hips, or pelvis

When to seek urgent care: Go to an urgent care clinic or emergency department immediately if you become unable to urinate at all (acute urinary retention), develop a high fever and chills alongside painful urination or pelvic pain, or experience sudden weakness or numbness in your legs or loss of bladder or bowel control.

Checklist and Questions for Your Next Doctor’s Visit

Before your appointment, review these four preparation steps and bring the questions below to guide the conversation with your clinician:

1. Map your family history: Check whether your father, brothers, or sons have ever had prostate cancer, and find out whether anyone was diagnosed before age 65. Ask about family history of breast, ovarian, or pancreatic cancers as well, which can point to shared inherited mutations like BRCA1 or BRCA2.
2. Check your medication list: Tell your doctor if you take 5-alpha-reductase inhibitors such as finasteride or dutasteride (prescribed for an enlarged prostate or male pattern hair loss). These medications typically lower PSA levels by roughly half, meaning your doctor must adjust how your PSA threshold is interpreted. Do not stop taking prescribed medications before your blood draw unless instructed by your prescriber.
3. Time your blood draw properly: Avoid ejaculation, heavy cycling, or vigorous workouts that press on the saddle area for 48 hours before your lab appointment, and reschedule the test if you have an active urinary tract or prostate infection.
4. Bring past lab records: If you have had a PSA test at another clinic or health fair, bring the exact numerical result and date so your doctor can track your multi-year trend.

Questions to ask your doctor:

• “Given my age, race, and family history, should I be on an annual or every-two-year PSA schedule?”
• “Are any of my current medications or supplements likely to lower or raise my PSA reading?”
• “If my PSA comes back at 3.0 ng/mL or higher (or 6.5 ng/mL if I am 70 or older), what is your protocol for repeating the test and ordering an MRI before considering a biopsy?”
• “If we ever find a slow-growing, low-risk prostate cancer, would I be a candidate for active surveillance?”

Frequently Asked Questions

Do I still need a digital rectal exam (DRE) for prostate cancer screening?

No, major US screening guidelines—including the 2026 American Cancer Society screening guidelines and the USPSTF—no longer recommend a routine digital rectal exam as a primary screening test for men without symptoms. Studies show that adding a routine DRE to a PSA blood test does not reliably improve early cancer detection during routine checkups. However, a doctor may still perform a DRE as part of a diagnostic workup if your PSA level is elevated or if you come in with urinary symptoms.

What PSA level is considered high under the new guidelines?

Rather than using a single cutoff for all adults, the 2026 ACS guideline uses age-adjusted thresholds to decide who needs a repeat test. For men ages 45 to 69, a PSA of 3.0 ng/mL or higher is considered elevated; for men ages 70 to 74, the threshold is 6.5 ng/mL or higher. Because non-cancerous prostate growth and temporary irritation can push PSA past these numbers, a single result above the cutoff must be confirmed with a repeat blood draw 2 weeks to 3 months later.

If my PSA is below 3.0 ng/mL, could I still have prostate cancer?

Yes, although the likelihood of harboring an aggressive tumor is much lower. As the National Cancer Institute overview of the PSA test explains, there is no single PSA number that completely rules prostate cancer in or out. That is why guidelines recommend repeating the test every one to two years based on your risk category: tracking whether your PSA stays steady or rises sharply over time is much more informative than looking at one isolated lab value.

Why do guidelines recommend stopping routine PSA screening at age 75?

Most prostate cancers detected by screening grow slowly over many years, meaning it typically takes at least 10 years for early detection and treatment to translate into a survival benefit. In men aged 75 and older, competing health risks rise while the physical toll of biopsies, radiation, or surgery becomes harder to tolerate. Only exceptionally healthy men aged 75 to 79—especially those whose PSA levels have been creeping up on prior tests—are advised to discuss continuing tests with their clinician, and screening is discouraged for everyone at age 80.

Does health insurance cover PSA screening under the updated guidelines?

Most private health insurance plans, Medicare Part B, and Medicaid cover periodic PSA blood tests for men in the recommended age brackets, though out-of-pocket costs can vary depending on whether the test is coded as preventive screening or diagnostic follow-up. According to the CDC prostate cancer screening guidance, men should check directly with their insurance plan before testing—especially if a confirmed high PSA leads to follow-up prostate MRI scans or specialized biomarker blood tests, which may require prior authorization.